The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | MAVORIC trial: mogamulizumab for R/R CTC
At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu from Sidney Kimmel Cancer Center, Philadelphia, PA, describes the MAVORIC trial (NCT01728805) investigating the efficacy of vorinostat with the novel monoclonal antibody mogamulizumab in patients with refractory or relapsed cutaneous T-cell lyphoma (CTCL). Dr Pierluigi shares the trial design and highlights that further research is needed in order to tackle the unmet needs of CTCL.
